Screener
Theravance Biopharma TBPH Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$5.9M-111% | -$4.93M+63.7% | $61.02M+493% | $3.62M+128% | $54.84M+432% | ||
| $367K-10.3% | $381K-7.7% | $399K-5.5% | $405K-5.6% | $409K-4.2% | ||
| $5.99M+31.9% | $4.5M-7.6% | $4.48M-23.1% | $4.58M-7.8% | $4.54M-15.5% | ||
| —— | $73.28M+70.3% | —— | —— | $208.07M+4,813% | ||
| —— | —— | $8K-95.8% | —— | —— | ||
| -$60.4M-66.6% | $52.59M+71.7% | $0-100% | -$100.25M-476% | -$36.26M— | ||
| -$967K-92.2% | -$5.58M-553% | -$1.49M-308% | -$400K-7.5% | -$503K-1,043% | ||
| —— | $120.3M+65.2% | —— | —— | $171.31M— |
FAQ
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
